According to exclusive early information obtained by vbdata.com, RocRock Biotechnology has recently completed a Series A financing round of RMB 50 million to advance its globally leading macrophage-based drug development and clinical translation.

The proceeds will be primarily allocated to building the company's world-class macrophage drug platform, accelerating IND-enabling activities and Phase I clinical progress of its proprietary third-generation CAR-M therapy targeting HER2, as well as supporting preclinical studies and investigator-initiated trials for pipelines including pancreatic cancer and lung cancer. The successful completion of this financing round not only demonstrates strong market recognition of the company's innovative capabilities and R&D progress in the macrophage therapeutics field, but also establishes a solid foundation for subsequent clinical translation.

Platform-driven approach to address key challenges in developing effective CAR-R therapies

RocRock Biotechnology has fundamentally addressed the core challenges of autologous CAR-M therapy—namely difficult transduction, high costs, long production cycles, and limited anti-tumor efficacy—through its proprietary suite of four technology platforms.

Viral Vector Breakthrough: RocRoc's self-developed, macrophage-specific viral modification technology has boosted the transduction efficiency of adenovirus and lentivirus in macrophages to over 90%, solving the industry-wide pain point of low gene delivery efficiency in CAR-M.

Third-Generation CAR-M: RocRoc's world-first third-generation CAR-M construct incorporates cytokines essential for macrophage autologous proliferation and activation. This promotes the long-term survival of CAR-M cells and remodels the tumor microenvironment. This platform has already completed an IIT clinical trial involving 10 patients.
In Vivo CAR-M Technology: The company's proprietary iterative delivery technology can be regarded as a "next-generation operating system" for genetic medicine. It enables any nucleic acid-based drug to achieve a performance leap when integrated with this system. This foundational positioning makes it an indispensable technological platform within the future gene and cell therapy ecosystem.

Compelling Clinical Data Validates New Paradigm of "High-Quality Life"

Leveraging its proprietary technology platform, RocRock has established a pipeline of multiple preclinical programs targeting major disease areas such as solid tumors and chronic diseases. Among them, the RR-M01 program for HER2-positive solid tumors is the most advanced. The study has already enrolled more than half of the planned participants, with data demonstrating a favorable safety profile and preliminary efficacy signals to date.
Dual Improvement in Efficacy and Quality of Life: RR-M01 injection has demonstrated a favorable safety profile and encouraging preliminary efficacy in patients with advanced solid tumors who have failed or are intolerant to DS-8201 (Trastuzumab Deruxtecan) treatment. Clinical data show a Disease Control Rate (DCR) of 71.4% post-treatment. Patients have not only achieved effective tumor control but also experienced comprehensive improvement in their quality of life. This combined benefit directly addresses the core challenge in current advanced solid tumor therapy—the difficulty of balancing efficacy with quality of life—offering new hope for patients who have failed multiple prior lines of therapy.
Single Administration Achieves Long-Term Disease Stability: The first subject, who received a single dose of RR-M01 in December 2023, has now achieved a Progression-Free Survival (PFS) of 23 months to date, without receiving any other anti-tumor therapies during this period. Radiological assessments confirm sustained stable tumor size with no progression compared to baseline, representing genuine long-term, high-quality disease control and survival.

Founder's Statement: Yin Xiushan, Founder of RocRock Biotechnology, stated, "We extend our sincere gratitude to both new and existing shareholders for their strong recognition and steadfast support. This financing round represents a critical milestone in the company's development. We remain unwavering in our focus on the pioneering field of macrophage-based therapeutics, determined to overcome the core challenge of solid tumor treatment. Our mission is to vigorously advance the development of safe, effective, and accessible innovative therapies to benefit cancer patients as soon as possible. The company will continue to increase R&D investment, strengthen our product pipeline, and actively seek collaboration opportunities with leading pharmaceutical companies globally to accelerate the commercialization of our technologies."

Reference: https://www.vbdata.cn/1519050100